The P/E ratio for Rigel Pharmaceuticals stock stands at 18.39 as of Apr 2, 2025. The calculation is based on the latest EPS of $0.99 and the stock price of $18.21 per share.
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | 16.99 | N/A | $16.82 | $0.99 |
2023 | N/A | N/A | $14.5 | -$1.44 |
2022 | N/A | N/A | $15 | -$3.44 |
2021 | N/A | N/A | $26.5 | -$1.1 |
2020 | N/A | N/A | $35 | -$1.8 |
2019 | N/A | N/A | $21.4 | -$4 |
2018 | N/A | N/A | $23 | -$4.4 |
2017 | N/A | N/A | $38.8 | -$6.2 |
2016 | N/A | N/A | $23.8 | -$7.3 |
2015 | N/A | N/A | $30.3 | -$5.8 |
2014 | N/A | N/A | $22.7 | -$10.4 |
2013 | N/A | N/A | $28.5 | -$10.2 |
2012 | N/A | N/A | $65 | -$13.2 |
2011 | N/A | N/A | $78.9 | -$13.6 |
2010 | 10.32 | N/A | $75.3 | $7.3 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Dec 2024 | 16.99 | -79% | $16.82 | $0.99 |
Sep 2024 | 80.9 | N/A | $16.18 | $0.2 |
Jun 2024 | N/A | N/A | $8.22 | -$0.84 |
Mar 2024 | N/A | N/A | $14.8 | -$1.16 |
Dec 2023 | N/A | N/A | $14.5 | -$1.44 |
Sep 2023 | N/A | N/A | $10.8 | -$1.45 |
Jun 2023 | N/A | N/A | $12.9 | -$2.22 |
Mar 2023 | N/A | N/A | $13.2 | -$2.64 |
Dec 2022 | N/A | N/A | $15 | -$3.44 |
Sep 2022 | N/A | N/A | $11.8 | -$4.9 |
Jun 2022 | N/A | N/A | $11.3 | -$5 |
Mar 2022 | N/A | N/A | $29.9 | -$5 |
Dec 2021 | N/A | N/A | $26.5 | -$1.1 |
Sep 2021 | N/A | N/A | $36.3 | -$0.9 |
Jun 2021 | N/A | N/A | $43.4 | -$0.5 |
When compared to its peer stocks AZN and AMGN, RIGL's PE ratio is lower.
Stock name | PE ratio | Market cap |
---|---|---|
RIGL Rigel Pharmaceuticals Inc | 17.74 | $313.67M |
AZN Astrazeneca plc | 32.72 | $230.36B |
AMGN Amgen Inc | 40.71 | $166.64B |
SGMO Sangamo Therapeutics Inc | N/A | $141.32M |
XOMA XOMA Corp | N/A | $240.17M |
RIGL stock has a price to earnings ratio of 18.39 as of Apr 2, 2025.
To determine the P/E ratio, divide the latest stock price by the TTM earnings per share (EPS). As of today (Apr 2, 2025), Rigel Pharmaceuticals's share price is $18.21. The company's earnings per share for the trailing twelve months (TTM) ending Dec 2024 is $0.99. Therefore, Rigel Pharmaceuticals's price to earnings ratio for today is 18.39. PE RATIO(18.39) = STOCK PRICE($18.21) / TTM EPS($0.99)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.